Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters)

Albert Fournier, Roxana Oprisiu, Jean Michel Achard, Olaf H. Klungel, Hubert G.M. Leufkens, Anthonius De Boer, W. T. Longstreth, Robert C. Kaplan, Nicholas L. Smith, Bruce M. Psaty

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)2152-2153
Number of pages2
JournalArchives of internal medicine
Volume161
Issue number17
DOIs
StatePublished - Sep 24 2001
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Fournier, A., Oprisiu, R., Michel Achard, J., Klungel, O. H., Leufkens, H. G. M., De Boer, A., Longstreth, W. T., Kaplan, R. C., Smith, N. L., & Psaty, B. M. (2001). Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters). Archives of internal medicine, 161(17), 2152-2153. https://doi.org/10.1001/archinte.161.17.2152